MEMBRANOUS LUPUS NEPHROPATHY

三种免疫抑制剂方案的疗效及毒副反应 将在膜性狼疮性肾病患者中进行评价 在12个月的研究期间。 肾功能的详细检查， 肾小球选择透过性和肾活检形态学将是 在治疗开始和结束时进行。 患者 系统性红斑狼疮、肾病范围蛋白尿和 活检证实的膜性肾病将接受以下治疗： 隔日泼尼松，并将随机接受：a）无 附加治疗（对照组），B）静脉脉冲 环磷酰胺高达1.0克/平方米体表面积 每隔一个月，共6次，或c）口服环孢菌素A， 至200 mg/m2体表面积， 11个月 狼疮活动性、肾功能检查和药物 将密切监测毒性。 分析将包括 肾小球疾病有利结局的数量比较 功能和病理以及出现的药物相关毒性 在12个月的研究结束时，每个治疗组。

The efficacy and toxicity of three immunosuppressive drug regimens will be evaluated in patients with membranous lupus nephropathy over a 12 month study period. Detailed tests of renal function, glomerular permselectivity and kidney biopsy morphology will be conducted at the beginning and end of treatment. Patients with systemic lupus erythematosus, nephrotic range proteinuria and biopsy documented membranous nephropathy will be treated with alternate day prednisone and will be randomized to receive: a) no additional therapy (control group), b) intravenous pulse cyclophosphamide up to 1.0 gram per square meter body surface area every other month for 6 total doses, or c) oral cyclosporin A up to 200 mg per square meter body surface area daily for a total of 11 months. Lupus disease activity, renal function tests and drug toxicities will be monitored closely. Analysis will include comparison of the number of favorable outcomes of glomerular function and pathology as well as drug-related toxicities appearing in each treatment group at the end of 12 months of study.